Research for imainmotherany by iron-chelation against hepatocellular carcinoma

干扰素y （IFNy）通过结合特异性受体发挥作用。IFNy受体由R1和R2亚基组成。在正常细胞和癌细胞中，R1是组成性表达的，但R2通常是下调的。R2的下调导致癌细胞对IFNy的抗肿瘤作用产生抵抗。为了增加癌细胞对IFNy的易感性，有必要增加R2在癌细胞中的表达。由于铁螯合作用增加了T细胞淋巴瘤中R2的表达，我们在肝细胞癌（2006年）和结肠癌（2007年）中测试了铁螯合作用的效果。在这两种癌细胞中，铁螯合有效地增加了R2的表达，并导致IFNy的易感性增加，包括生长抑制和细胞凋亡诱导。有人认为铁螯合作用。此外，IFNy是治疗肝细胞癌和结肠癌的新方法。

Interferon y (IFNy) exerts its effect by biding to the specific receptor. IFNy receptor comprise of R1 and R2 subunits. In normal cells and cancer cells, R1 is constitutively expressed, but R2 is usually downregulated. Downregulation of R2 results in the resistance of cancer cells to anti-neoplastic effect of IFNy. It is necessary to increase the expression of R2 in cancer cells, in order to increase the susceptibility to IFNy. Because it has been shown that iron-chelation increase the expression of R2 in T cell lymphoma, we tested the effect of the iron-chelation in hepatocellular carcinoma (in year of 2006) and colon cancer (in year 2007). In both cancer cells, iron-chelation effectively increased the expression of R2, and resulted in increased susceptibility of IFNy, including growth inhibition and apoptosis-induction. It is suggested that iron-chelation. Plus IFNy is promising new method to treat hepatocellular carcinoma and colon cancer.